ev3 — Q1 2010 Earnings Presentation
19 slides from ev3's earnings presentation, Apr 29, 2010
Slide 1: 1Q 2010 Highlights
1Q 2010 Highlights April 29, 2010
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "inten
Slide 3: Use of Non-GAAP Financial Measures
3 Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation. ev3 uses non-GAAP financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. H
Slide 4: Q1 '10 Financial Summary
4 Q1 '10 Financial Summary Net sales of $123.9 million +23% vs. Q1 2009; +21% constant currency* Peripheral vascular sales +13% vs. Q1 2009; +11% constant currency* Plaque excision +12% vs. Q1 2009, +12% constant currency* Peripheral stents +6% vs. Q1 2009; +4% constant currency* Thrombectomy and em
Slide 5: Recent Operational Highlights - Peripheral Vascular
5 Recent Operational Highlights - - Peripheral Vascular Continuing progress in U.S. launch of TurboHawk(tm) Plaque Excision System Incremental opportunity to treat calcified above-the-knee lesions PowerCross(tm) .018 PTA balloon launched globally in 1Q'10 - in addition to EverCross(tm) and NanoCross
Slide 6: A Closer Look: DEFINITIVE AR Pilot Study
6 A CLOSER LOOK: DEFINITIVE AR (Anti-Restenosis) Pilot Study Pilot study will evaluate combination of Hawk Plaque Excision and MEDRAD's Cotavance(tm) drug-coated PTA balloon for treatment of lower extremity peripheral arterial disease Combination may allow for enhanced drug uptake, improved acute re
Slide 7: Recent Operational Highlights - Neurovascular
7 Recent Operational Highlights - - Neurovascular International launch for Pipeline(tm) Embolization Device (PED) and Solitaire FR Revascularization Device for ischemic stroke progressing very well Now have approx. 113 physicians who are certified or working towards Pipeline certification Early laun
Slide 8: A Closer Look: SWIFT Study
8 A CLOSER LOOK: SWIFT (Solitaire with Intention for Thrombectomy) Study Investigational Use Only in the United States: Not FDA approved or cleared Flow restoration upon deployment Clot retrieval Multi-center, prospective, randomized controlled trial comparing recanalization rates of Solitaire(tm) F
Slide 9: Actual Results vs. Last Quarter & Year Ago
9 Actual Results vs. Last Quarter & Year Ago * Constant Currency; For reconciliations, see our website at www.ev3.net. ** All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q1 2009 is also adjusted for a non-cash FoxHollow lease reserve adjustment and a reali
Slide 10: Total Q1 '10 Revenue Growth of 21%*
10 Total Q1 '10 Revenue Growth of 21%* Total International ($M) +24%* Worldwide Peripheral Vascular ($M) +11%* Worldwide Neurovascular ($M) +38%* *Constant currency compared to Q1 2009; For reconciliations, see our website at www.ev3.net. +21%* Q1 Total Worldwide Sales ($M) Q1 2009 2010 Q1 Q1
Slide 11: Key 2010 Financial Indicators
11 Key 2010 Financial Indicators $M Operating Margin Net Sales Adjusted EPS1 Cash Flow from Operations $ SG&A as % of net sales 50% 49% 47% 1. All quarters presented are adjusted for amortization, non-cash stock-based compensation and charges relating to the change in fair value of contingent consid
Slide 12: Balance Sheet is Strengthening - We are Generating Cash
12 Balance Sheet is Strengthening - - We are Generating Cash Cash / Cash Equivalents Cash flow from operating activities totaled $17.3M in Q1'10 Cash/cash equivalents increased $18.8M in Q1'10 vs Q4'09 Total debt decreased to $5.8M *Q2 09 included $26.2M payment for Chestnut Medical
Slide 13: Improving Cost Structure - Continuing Progress
13 Improving Cost Structure - Continuing Progress Gross Margin % of sales SG&A % of sales Improved manufacturing efficiencies, volume growth and favorable product mix Continued focus on leveraging cost structure and improving margins
Slide 14: Financial Summary: Continuing to Improve Performance
14 Financial Summary: Continuing to Improve Performance Net Sales $123,854 $100,395 $109,086 $112,838 $126,753 Gross Profit $94,627 $69,407 $78,608 $84,230 $96,214 Gross Margin 76.4% 69.1% 72.1% 74.6% 75.9% Net Income (Loss) $9,864 $(1,809) $23,989 $6,736 $13,001 Adjusted EPS per Diluted Share* $0.2
Slide 15: Guidance - As of April 29, 2010
15 Guidance - As of April 29, 2010 Full-Year 2010 Guidance Revenues: Q2 2010: $129 to $133 million Full-Year 2010: $520 to $530 million Adjusted EPS1 per diluted share: Q2 2010: $0.18 to $0.211,2 Full-Year 2010: $0.87 to $0.921,2 Adjusted EPS guidance is based on weighted average diluted shares outs
Slide 16: Business Model Structure - Select P&L Information
16 2008 % of sales 2007 2010 Goal Business Model Structure - - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 73% Selling, general & administrative* 55% 69% 50% Research & development 12% 17% 11% Stock-based comp, amortization & contingent consideration 11% 11% 10% Adjusted net inc
Slide 17: Growth Drivers / Milestones Next 3-9 Months
Growth Drivers / Milestones Next 3-9 Months Procedure penetration, improving margins and leveraging existing cost structure Peripheral Vascular business increased sales force productivity growth in plaque excision business - TurboHawk(tm) above-the-knee new product launches TurboHawk(tm) below-the-k
Slide 18: Save the Date...
Save the Date... ev3 Analyst and Investor Meeting Thursday, September 23, 2010 5:00pm - 7:30pm Eastern Time During TCT 2010 Conference in Washington, D.C. Registration information and agenda will be available in August. see ° ee covrah nent V3 Jourendovascutar company”
Slide 19: Contact Info
NASDAQ: EVVV www.ev3.net Contact Info: Julie Tracy - Sr. VP, Chief Communications Officer (949) 680-1375 jtracy@ev3.net